|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sartore-Bianchi A, Moroni M, Veronese S,
Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S,
Colucci G, et al: Epidermal growth factor receptor gene copy number
and clinical outcome of metastatic colorectal cancer treated with
panitumumab. J Clin Oncol. 25:3238–3245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Vecchio Blanco G, Paoluzi OA, Sileri
P, Rossi P, Sica G and Pallone F: Familial colorectal cancer
screening: When and what to do? World J Gastroenterol.
21:7944–7953. 2015.PubMed/NCBI
|
|
6
|
Jonker DJ, Karapetis CS, Harbison C,
O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N,
Price TJ, et al: Epiregulin gene expression as a biomarker of
benefit from cetuximab in the treatment of advanced colorectal
cancer. Br J Cancer. 110:648–655. 2014. View Article : Google Scholar :
|
|
7
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bos JL, Fearon ER, Hamilton SR, Verlaan-de
Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of
ras gene mutations in human colorectal cancers. Nature.
327:293–297. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohnishi T, Tomita N, Monden T, Ohue M,
Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, et al:
A detailed analysis of the role of K-ras gene mutation in the
progression of colorectal adenoma. Br J Cancer. 75:341–347. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Puerta-García E, Cañadas-Garre M and
Calleja-Hernández MA: Molecular biomarkers in colorectal carcinoma.
Pharmacogenomics. 16:1189–1222. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Jakubowski M and Hunt JL: KRAS gene
mutation in colorectal cancer is correlated with increased
proliferation and spontaneous apoptosis. Am J Clin Pathol.
135:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andreyev HJ, Norman AR, Cunningham D,
Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N,
et al: Kirsten ras mutations in patients with colorectal cancer:
The 'RASCAL II' study. Br J Cancer. 85:692–696. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang YS, Chang SJ, Yeh KT, Lin TH and
Chang JG: RAS, BRAF, and TP53 gene mutations in Taiwanese
colorectal cancer patients. Onkologie. 36:719–724. 2013.PubMed/NCBI
|
|
14
|
Palmirotta R, Savonarola A, Ludovici G, De
Marchis ML, Covello R, Ettorre GM, Ialongo C and Guadagni F:
Concurrent mutation in exons 1 and 2 of the K-ras oncogene in
colorectal cancer. Folia Histochem Cytobiol. 49:729–733. 2011.
View Article : Google Scholar
|
|
15
|
Salhab N, Jones DJ, Bos JL, Kinsella A and
Schofield PF: Detection of ras gene alterations and ras proteins in
colorectal cancer. Dis Colon Rectum. 32:659–664. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomas RJ, Liu YS, St Clair F, Norris PM,
Valentine R and Phillips WA: Frequency and clinico-pathological
associations of ras mutations in colorectal cancer in the Victorian
population. Aust NZ J Surg. 67:233–238. 1997. View Article : Google Scholar
|
|
17
|
Yaeger R, Cowell E, Chou JF, Gewirtz AN,
Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, et al:
RAS mutations affect pattern of metastatic spread and increase
propensity for brain metastasis in colorectal cancer. Cancer.
121:1195–1203. 2015. View Article : Google Scholar :
|
|
18
|
Kiaris H and Spandidos D: Mutations of ras
genes in human tumors (Review). Int J Oncol. 7:413–421.
1995.PubMed/NCBI
|
|
19
|
Irahara N, Baba Y, Nosho K, Shima K, Yan
L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM and Ogino S:
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol.
19:157–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Glarakis IS, Savva S and Spandidos DA:
Activation of the ras genes in malignant and premalignant
colorectal tumors. Oncol Rep. 5:1451–1454. 1998.PubMed/NCBI
|
|
21
|
Boidot R, Chevrier S, Julie V, Ladoire S
and Ghiringhelli F: HRAS G13D, a new mutation implicated in the
resistance to anti-EGFR therapies in colorectal cancer, a case
report. Int J Colorectal Dis. 31:1245–1246. 2016. View Article : Google Scholar
|
|
22
|
Spandidos DA, Sourvinos G, Tsatsanis C and
Zafiropoulos A: Normal ras genes: Their onco-suppressor and
pro-apoptotic functions (Review). Int J Oncol. 21:237–241.
2002.PubMed/NCBI
|
|
23
|
Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S,
Cao D, Zhou L, Zhang A, Liu D, et al: Overexpression of wild-type
EGFR is tumorigenic and denotes a therapeutic target in non-small
cell lung cancer. Oncotarget. 7:3884–3896. 2016.
|
|
24
|
Lim SO, Park YM, Kim HS, Quan X, Yoo JE,
Park YN, Choi GH and Jung G: Notch1 differentially regulates
oncogenesis by wild-type p53 overexpression and P53 mutation in
grade III hepatocellular carcinoma. Hepatology. 53:1352–1362. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McDermott U, Longley DB and Johnston PG:
Molecular and biochemical markers in colorectal cancer. Ann Oncol.
13(Suppl 4): 235–245. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang JL, Liu DX, Zhen SJ, Zhou YG, Zhang
DJ, Yang LY, Chen HB and Feng Q: A novel anti-p21R as scFv antibody
reacting specifically with human tumour cell lines and primary
tumour tissues. BMC Cancer. 16:1312016. View Article : Google Scholar
|
|
27
|
Budwit-Novotny DA, McCarty KS, Cox EB,
Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr:
Immunohistochemical analyses of estrogen receptor in endometrial
adenocarcinoma using a monoclonal antibody. Cancer Res.
46:5419–5425. 1986.PubMed/NCBI
|
|
28
|
Ferretti G, Felici A, Papaldo P, Fabi A
and Cognetti F: HER2/neu role in breast cancer: From a prognostic
foe to a predictive friend. Curr Opin Obstet Gynecol. 19:56–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baselga J, Manikhas A, Cortés J, Llombart
A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S,
Goldfarb RH, et al: Phase III trial of nonpegylated liposomal
doxorubicin in combination with trastuzumab and paclitaxel in
HER2-positive metastatic breast cancer. Ann Oncol. 25:592–598.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guan Z, Xu B, DeSilvio ML, Shen Z,
Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, et
al: Randomized trial of lapatinib versus placebo added to
paclitaxel in the treatment of human epidermal growth factor
receptor 2-overexpressing metastatic breast cancer. J Clin Oncol.
31:1947–1953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang F, Yu Y, Xing L and Chen M:
Cetuximab combined with chemotherapy is beneficial for patients
with advanced non-small cell lung cancer after EGFR-tyrosine kinase
inhibitors failure. Int J Clin Exp Med. 8:16140–16148.
2015.PubMed/NCBI
|
|
33
|
Socinski MA: Antibodies to the epidermal
growth factor receptor in non small cell lung cancer: current
status of matuzumab and panitumumab. Clin Cancer Res.
13:s4597–4601. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boland W and Bebb G: The emerging role of
nimotuzumab in the treatment of non-small cell lung cancer.
Biologics. 4:289–298. 2010.PubMed/NCBI
|
|
35
|
Hand PH, Thor A, Wunderlich D, Muraro R,
Caruso A and Schlom J: Monoclonal antibodies of predefined
specificity detect activated ras gene expression in human mammary
and colon carcinomas. Proc Natl Acad Sci USA. 81:5227–5231. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Viola MV, Fromowitz F, Oravez S, Deb S and
Schlom J: ras oncogene P21 expression is increased in premalignant
lesions and high grade bladder carcinoma. J Exp Med. 161:1213–1218.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ohuchi N, Thor A, Page DL, Hand PH, Halter
SA and Schlom J: Expression of the 21,000 molecular weight ras
protein in a spectrum of benign and malignant human mammary
tissues. Cancer Res. 46:2511–2519. 1986.PubMed/NCBI
|
|
38
|
Ghosh AK, Moore M and Harris M:
Immunohistochemical detection of ras oncogene P21 product in benign
and malignant mammary tissue in man. J Clin Pathol. 39:428–434.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ohuchi N, Hand PH, Merlo G, Fujita J,
Mariani-Costantini R, Thor A, Nose M, Callahan R and Schlom J:
Enhanced expression of c-Ha-ras p21 in human stomach
adenocarcinomas defined by immunoassays using monoclonal antibodies
and in situ hybridization. Cancer Res. 47:1413–1420.
1987.PubMed/NCBI
|
|
40
|
Johnson TL, Lloyd RV and Thor A:
Expression of ras oncogene P21 antigen in normal and proliferative
thyroid tissues. Am J Pathol. 127:60–65. 1987.PubMed/NCBI
|
|
41
|
Scambia G, Catozzi L, Benedetti Panici P,
Ferrandina G, Almadori G, Paludetti G, Cadoni G, Distefano M,
Piffanelli A and Mancuso S: Expression of ras oncogene P21 protein
in normal and neoplastic laryngeal tissues: Correlation with
histopathological features and epidermal growth factor receptors.
Br J Cancer. 69:995–999. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang JL, Pan XY, Zhao WX, Hu QC, Ding F,
Feng Q, Li GY and Luo Y: The antitumor efficacy of a novel
adenovirus-mediated anti-p21Ras single chain fragment variable
antibody on human cancers in vitro and in vivo. Int J Oncol.
48:1218–1228. 2016.PubMed/NCBI
|
|
43
|
Sammoud S, Khiari M, Semeh A, Amine L,
Ines C, Amira A, Lilia K, Taher K, Sabeh M and Saadia B:
Relationship between expression of ras P21 oncoprotein and mutation
status of the K-ras gene in sporadic colorectal cancer patients in
Tunisia. Appl Immunohistochem Mol Morphol. 20:146–152. 2012.
View Article : Google Scholar
|
|
44
|
Allen DC, Foster H, Orchin JC and Biggart
JD: Immunohistochemical staining of colorectal tissues with
monoclonal antibodies to ras oncogene p21 product and carbohydrate
determinant antigen 19-9. J Clin Pathol. 40:157–162. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sun XF, Wingren S, Carstensen JM, Stål O,
Hatschek T, Boeryd B, Nordenskjöld B and Zhang H: ras P21
expression in relation to DNA ploidy, S-phase fraction and
prognosis in colorectal adenocarcinoma. Eur J Cancer. 27:1646–1649.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morris VK, Lucas FA, Overman MJ, Eng C,
Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P,
et al: Clinicopathologic characteristics and gene expression
analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal
cancer. Ann Oncol. 25:2008–2014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Elsabah MT and Adel I: Immunohistochemical
assay for detection of K-ras protein expression in metastatic
colorectal cancer. J Egypt Natl Canc Inst. 25:51–56. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hirvikoski P, Auvinen A, Servomaa K, Kiuru
A, Rytömaa T, Makkonen K and Kosma VM: K-ras and P53 mutations and
overexpressions as prognostic factors in female rectal carcinoma.
Anticancer Res. 19:685–691. 1999.PubMed/NCBI
|
|
49
|
Okulczyk B, Kovalchuk O, Piotrowski Z,
Myśliwiec P and Chyczewski L: Clinical usefulness of K-RAS mutation
detection in colorectal cancer and in surgical margins of the
colon. Rocz Akad Med Bialymst. 49(Suppl 1): 52–54. 2004.
|
|
50
|
Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang
H, Liao YH, Li Y, Lewis MT, Edwards D, et al: Wild-type N-Ras,
overexpressed in basal-like breast cancer, promotes tumor formation
by inducing IL-8 secretion via JAK2 activation. Cell Rep.
12:511–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Spandidos A and Wilkie NM: The normal
human H-ras1 gene can act as an onco-suppressor. Br J Cancer Suppl.
9:67–71. 1988.PubMed/NCBI
|
|
52
|
Spandidos DA, Frame M and Wilkie NM:
Expression of the normal H-ras1 gene can suppress the transformed
and tumorigenic phenotypes induced by mutant ras genes. Anticancer
Res. 10:1543–1554. 1990.PubMed/NCBI
|
